ADVERTISEMENT
Search

 

Press Releases

 

2

May

2022

APhA appreciates CMS’ elimination of retroactive DIR fees

Though more actions are needed to address PBMs’ harmful business practices

Author: Renee Kalu

WASHINGTON, D.C.—CMS has issued a final rule eliminating Part D plans’ and PBMs’ use of retroactive direct and indirect remuneration (DIR) fees beginning on January 1, 2024 (contract year 2024). The American Pharmacists Association (APhA) and many of its members submitted comments to CMS on the proposal. APhA appreciates CMS’ efforts to end the uncertainty and lack of drug cost transparency at the pharmacy caused by retroactive DIR fees.

Comments (0)
Number of views (7808)
Article rating: No rating

22

Apr

2022

APhA addresses AMA’s inaccurate description of H.R. 7213 and viewpoints of most physicians working alongside pharmacists

Author: Renee Kalu

WASHINGTON, DC – The American Pharmacists Association released the following statement in response to an April 12, 2022, letter from the American Medical Association (AMA) to Representatives Kind and McKinley regarding H.R. 7213, the “Equitable Community Access to Pharmacist Services Act.”  

Comments (0)
Number of views (11748)
Article rating: No rating

13

Apr

2022

APhA releases Community Pharmacy Workplace Summit Report to address drivers impacting workplace and well-being

Author: Renee Kalu

WASHINGTON, D.C.—The American Pharmacists Association (APhA) is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that results in improved workplaces, well-being, and the ability to meet ethical obligations to patient safety. 

Comments (0)
Number of views (4557)
Article rating: No rating

7

Mar

2022

New Study: Medicare could save seniors billions by fixing Part D incentives

Author: Renee Kalu

WASHINGTON, DC and BESSEMER, AL—Plan sponsors and PBMs who manage prescription drug benefits under Medicare Part D are shifting costs and risks to America’s seniors and taxpayers by artificially inflating prescription drug costs at the pharmacy counter, according to a groundbreaking new study released today.

Comments (0)
Number of views (5704)
Article rating: No rating

18

Feb

2022

APhA expresses disappointment at failed Federal Trade Commission vote to study PBMs’ anticompetitive business practices

APhA urges the Federal Trade Commission (FTC) to reach a consensus to not only study, but fix the broken PBM marketplace

Author: Renee Kalu

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to the FTC’s stalemate 2-2 vote today, which would have supported study of the competitive impact of contractual provisions, reimbursement adjustments, and other PBM practices affecting drug prices, including those practices that may disadvantage independent or specialty pharmacies.

Comments (0)
Number of views (3271)
Article rating: No rating
RSS
12
ADVERTISEMENT